Clinical Trial

A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The current clinical study will evaluate the GVGH Quadrivalent Pan-Salmonella vaccine for the first time in healthy adults in Africa. The purpose of the current Phase 1 study is to evaluate the safety, reactogenicity, and the immune response induced by the Pan-Salmonella vaccine.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-29
Trial Details
NCT Number NCT07663032
Lead Sponsor GlaxoSmithKline
Conditions Salmonella Infections
Enrollment 196 participants
Start Date 2026-06-24
Primary Completion 2027-11-14 (estimated)
Study Completion 2027-11-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-28